Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Memantine - Children's Medical Center Corporation/Merz Pharma

Drug Profile

Memantine - Children's Medical Center Corporation/Merz Pharma

Alternative Names: Akatinol; Axura; D-145; Ebixa; Extended-release memantine capsules - Allergan; Memantine hydrochloride; Memary; Namenda; Namenda XR; SUN Y7017; SUNY 017

Latest Information Update: 18 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Childrens Medical Center Corporation
  • Developer Allergan; Daiichi Sankyo Company; Forest Laboratories; Lundbeck A/S; Merz Pharma; Neurobiological Technologies; University of California, Davis
  • Class Amines; Analgesics; Antidementias; Antiparkinsonians; Antispastics; Antitussives; Eye disorder therapies; Organic bridged compounds; Small molecules
  • Mechanism of Action Nicotinic receptor antagonists; NMDA receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Dementia
  • Phase III Vascular dementia
  • Discontinued Asperger syndrome; Autistic disorder; Diabetic neuropathies; Fragile X syndrome; Glaucoma; Neuropathic pain

Most Recent Events

  • 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Alzheimer's-disease(Combination therapy) in Japan (PO, Immediate release)
  • 24 Dec 2018 Lundbeck completes a phase I trial in healthy volunteers in China (PO) (NCT03670095)
  • 28 Aug 2018 Lundbeck initiates a phase I trial in healthy volunteers in China (NCT03670095)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top